Charles Zhu
Stock Analyst at LifeSci Capital
(4.75)
# 621
Out of 4,429 analysts
278
Total ratings
55.8%
Success rate
20.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Maintained: Buy | $28 | $9.93 | +181.97% | 32 | Jun 15, 2026 | |
| IDYA IDEAYA Biosciences | Maintained: Buy | $62 | $31.23 | +98.53% | 50 | Jun 15, 2026 | |
| CNTX Context Therapeutics | Maintained: Buy | $6 | $0.6319 | +849.52% | 7 | Jun 15, 2026 | |
| NUVL Nuvalent | Downgraded: Hold | $124 | $123.43 | +0.46% | 26 | Jun 13, 2026 | |
| IMNM Immunome | Maintained: Buy | $40 | $18.74 | +113.45% | 16 | Jun 11, 2026 | |
| RCUS Arcus Biosciences | Initiated Coverage: Buy | $46 | $24.31 | +89.22% | 1 | Jun 6, 2026 | |
| RVMD Revolution Medicines | Maintained: Buy | $263 | $162.99 | +61.36% | 22 | Jun 1, 2026 | |
| STRO Sutro Biopharma | Maintained: Buy | $54 | $29.63 | +82.25% | 4 | May 30, 2026 | |
| TARA Protara Therapeutics | Maintained: Buy | $26 | $3.98 | +553.27% | 19 | May 20, 2026 | |
| MOLN Molecular Partners AG | Maintained: Buy | $12 | $3.98 | +201.51% | 16 | May 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $34 | $23.14 | +46.93% | 26 | May 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $2.02 | +197.03% | 12 | May 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $3.94 | +103.05% | 8 | May 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $22 → $28 | $17.69 | +58.28% | 10 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $22 | $6.25 | n/a | 1 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 | $27.97 | n/a | 3 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 → $20 | $4.13 | n/a | 6 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $26 | $34.54 | n/a | 4 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $45 → $39 | $12.64 | n/a | 4 | May 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $0.8503 | n/a | 3 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $31.53 | n/a | 3 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $30 → $20 | $1.13 | n/a | 4 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $2.00 | $0.43 | n/a | 1 | Nov 29, 2022 |
Kura Oncology
Jun 15, 2026
Maintained: Buy
Price Target: $28
Current: $9.93
Upside: +181.97%
IDEAYA Biosciences
Jun 15, 2026
Maintained: Buy
Price Target: $62
Current: $31.23
Upside: +98.53%
Context Therapeutics
Jun 15, 2026
Maintained: Buy
Price Target: $6
Current: $0.6319
Upside: +849.52%
Nuvalent
Jun 13, 2026
Downgraded: Hold
Price Target: $124
Current: $123.43
Upside: +0.46%
Immunome
Jun 11, 2026
Maintained: Buy
Price Target: $40
Current: $18.74
Upside: +113.45%
Arcus Biosciences
Jun 6, 2026
Initiated Coverage: Buy
Price Target: $46
Current: $24.31
Upside: +89.22%
Revolution Medicines
Jun 1, 2026
Maintained: Buy
Price Target: $263
Current: $162.99
Upside: +61.36%
Sutro Biopharma
May 30, 2026
Maintained: Buy
Price Target: $54
Current: $29.63
Upside: +82.25%
Protara Therapeutics
May 20, 2026
Maintained: Buy
Price Target: $26
Current: $3.98
Upside: +553.27%
Molecular Partners AG
May 16, 2026
Maintained: Buy
Price Target: $12
Current: $3.98
Upside: +201.51%
May 9, 2026
Rated: Buy
Price Target: $34
Current: $23.14
Upside: +46.93%
May 9, 2026
Maintained: Buy
Price Target: $6
Current: $2.02
Upside: +197.03%
May 2, 2026
Reiterated: Buy
Price Target: $8
Current: $3.94
Upside: +103.05%
Apr 30, 2026
Maintained: Buy
Price Target: $22 → $28
Current: $17.69
Upside: +58.28%
Jun 18, 2025
Initiated Coverage: Buy
Price Target: $22
Current: $6.25
Upside: n/a
May 24, 2024
Maintained: Buy
Price Target: $14
Current: $27.97
Upside: n/a
Jan 2, 2024
Maintained: Buy
Price Target: $12 → $20
Current: $4.13
Upside: n/a
Jun 13, 2023
Reiterated: Buy
Price Target: $26
Current: $34.54
Upside: n/a
May 9, 2023
Maintained: Buy
Price Target: $45 → $39
Current: $12.64
Upside: n/a
Mar 17, 2023
Maintained: Buy
Price Target: $5
Current: $0.8503
Upside: n/a
Jan 3, 2023
Maintained: Hold
Price Target: n/a
Current: $31.53
Upside: n/a
Jan 3, 2023
Maintained: Buy
Price Target: $30 → $20
Current: $1.13
Upside: n/a
Nov 29, 2022
Initiated Coverage: Buy
Price Target: $2.00
Current: $0.43
Upside: n/a